Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 409308, 14 pages
http://dx.doi.org/10.5402/2011/409308
Research Article

Tumor Vascular Morphology Undergoes Dramatic Changes during Outgrowth of B16 Melanoma While Proangiogenic Gene Expression Remains Unchanged

1Medical Biology Section, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
2Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden
3Fifth Medical Department, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany
4Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
5Department of Pathology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands

Received 3 August 2011; Accepted 7 September 2011

Academic Editors: S. Mohanam and H. Rizos

Copyright © 2011 Elise Langenkamp et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Folkman, “Angiogenesis: an organizing principle for drug discovery?” Nature Reviews Drug Discovery, vol. 6, no. 4, pp. 273–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. R. K. Jain, D. G. Duda, J. W. Clark, and J. S. Loeffler, “Lessons from phase III clinical trials on anti-VEGF therapy for cancer,” Nature Clinical Practice Oncology, vol. 3, no. 1, pp. 24–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. D. G. Duda, T. T. Batchelor, C. G. Willett, and R. K. Jain, “VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects,” Trends in Molecular Medicine, vol. 13, no. 6, pp. 223–230, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Langenkamp and G. Molema, “Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer,” Cell and Tissue Research, vol. 335, no. 1, pp. 205–222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. W. C. Aird, “Molecular heterogeneity of tumor endothelium,” Cell and Tissue Research, vol. 335, no. 1, pp. 271–281, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Bergers, K. Javaherian, K. M. Lo, J. Folkman, and D. Hanahan, “Effects of angiogenesis inhibitors on multistage carcinogenesis in mice,” Science, vol. 284, no. 5415, pp. 808–812, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Wood, G. Bold, E. Buchdunger et al., “PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration,” Cancer Research, vol. 60, no. 8, pp. 2178–2189, 2000. View at Google Scholar · View at Scopus
  8. J. Holash, P. C. Maisonpierre, D. Compton et al., “Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF,” Science, vol. 284, no. 5422, pp. 1994–1998, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Kumar, H. Kuniyasu, C. D. Bucana, M. R. Wilson, and I. J. Fidler, “Spatial and temporal expression of angiogenic molecules during tumor growth and progression,” Oncology Research, vol. 10, no. 6, pp. 301–311, 1998. View at Google Scholar · View at Scopus
  10. I. J. Fidler, “Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment,” Journal of the National Cancer Institute, vol. 93, no. 14, pp. 1040–1041, 2001. View at Google Scholar · View at Scopus
  11. J. M. Kułdo, J. Westra, S. A. Àsgeirsdóttir et al., “Differential effects of NF-κB and p38 MAPK inhibitors and combinations thereof on TNF-α- and IL-1β-induced proinflammatory status of endothelial cells in vitro,” American Journal of Physiology, vol. 289, no. 5, pp. C1229–C1239, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. A. W. Griffioen and G. Molema, “Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation,” Pharmacological Reviews, vol. 52, no. 2, pp. 237–268, 2000. View at Google Scholar · View at Scopus
  13. E. M. Conway, D. Collen, and P. Carmeliet, “Molecular mechanisms of blood vessel growth,” Cardiovascular Research, vol. 49, no. 3, pp. 507–521, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. R. K. Jain, “Molecular regulation of vessel maturation,” Nature Medicine, vol. 9, no. 6, pp. 685–693, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Carmeliet, “Mechanisms of angiogenesis and arteriogenesis,” Nature Medicine, vol. 6, no. 4, pp. 389–395, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Zeng, L. Qin, D. Zhao et al., “Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity,” Journal of Experimental Medicine, vol. 203, no. 3, pp. 719–729, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash, “Vascular-specific growth factors and blood vessel formation,” Nature, vol. 407, no. 6801, pp. 242–248, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Auguste, S. Lemiere, F. Larrieu-Lahargue, and A. Bikfalvi, “Molecular mechanisms of tumor vascularization,” Critical Reviews in Oncology/Hematology, vol. 54, no. 1, pp. 53–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. C. F. Chantrain, P. Henriet, S. Jodele et al., “Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases,” European Journal of Cancer, vol. 42, no. 3, pp. 310–318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Pinheiro, D. Bates, S. DebRoy, and D.a.t.R.C.t. Sarkar, “nlme: Linear and Nonlinear Mixed Effects Models,” R package version 3.1-892008.
  21. Y. Benjamini and Y. Hochberg, “Controlling the false discovery rate: a practical and powerful approach to multiple testing,” Journal of the Royal Statistical Society B, vol. 57, pp. 289–300, 1995. View at Google Scholar
  22. R Development Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2008.
  23. M. Thomas and H. G. Augustin, “The role of the angiopoietins in vascular morphogenesis,” Angiogenesis, vol. 12, no. 2, pp. 125–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Xu, D. Rodriguez, E. Petitclerc et al., “Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo,” Journal of Cell Biology, vol. 154, no. 5, pp. 1069–1079, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. J. E. Nör, R. S. Mitra, M. M. Sutorik, D. J. Mooney, V. P. Castle, and P. J. Polverini, “Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway,” Journal of Vascular Research, vol. 37, no. 3, pp. 209–218, 2000. View at Google Scholar · View at Scopus
  26. O. Stoeltzing, M. F. McCarty, J. S. Wey et al., “Role of hypoxia-inducible factor 1α in gastric cancer cell growth, angiogenesis, and vessel maturation,” Journal of the National Cancer Institute, vol. 96, no. 12, pp. 946–956, 2004. View at Google Scholar · View at Scopus
  27. P. Parsons-Wingerter, U. M. Chandrasekharan, T. L. McKay et al., “A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity,” Microvascular Research, vol. 72, no. 3, pp. 91–100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Hellström, L. K. Phng, J. J. Hofmann et al., “Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis,” Nature, vol. 445, no. 7129, pp. 776–780, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Liu, S. Kennard, and B. Lilly, “NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires Endothelial-expressed JAGGED1,” Circulation Research, vol. 104, no. 4, pp. 466–475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. L. E. Benjamin, I. Hemo, and E. Keshet, “A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF,” Development, vol. 125, no. 9, pp. 1591–1598, 1998. View at Google Scholar · View at Scopus
  31. I. Helfrich, I. Scheffrahn, S. Bartling et al., “Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma,” Journal of Experimental Medicine, vol. 207, no. 3, pp. 491–503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. O. H. Lee, J. Fueyo, J. Xu et al., “Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth,” Neoplasia, vol. 8, no. 5, pp. 419–428, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Gerhardt, M. Golding, M. Fruttiger et al., “VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia,” Journal of Cell Biology, vol. 161, no. 6, pp. 1163–1177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Kashiwagi, Y. Izumi, T. Gohongi et al., “NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels,” Journal of Clinical Investigation, vol. 115, no. 7, pp. 1816–1827, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Thurston and J. Kitajewski, “VEGF and Delta-Notch: Interacting signalling pathways in tumour angiogenesis,” British Journal of Cancer, vol. 99, no. 8, pp. 1204–1209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. J. L. Li, R. C. A. Sainson, W. Shi et al., “Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo,” Cancer Research, vol. 67, no. 23, pp. 11244–11253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. J. Van Amerongen, G. Molema, J. Plantinga, H. Moorlag, and M. J. A. Van Luyn, “Neovascularization and vascular markers in a foreign body reaction to subcutaneously implanted degradable biomaterial in mice,” Angiogenesis, vol. 5, no. 3, pp. 173–180, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Yano, S. Tanikawa, T. Fujie, M. Masutani, and T. Horie, “Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer,” European Journal of Cancer, vol. 36, no. 5, pp. 601–609, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Morrissey, L. D. True, M. P. Roudier et al., “Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases,” Clinical and Experimental Metastasis, vol. 25, no. 4, pp. 377–388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. M. Baldewijns, V. L. Thijssen, G. G. Van Den Eynden et al., “High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile,” British Journal of Cancer, vol. 96, no. 12, pp. 1888–1895, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Molema, “Angiogenesis: an integrative approach from science to medicine,” in Targeted Drug Delivery to the Tumor Neovasculature, W. D. Figg and J. Folkman, Eds., pp. 283–298, Springer, New York, NY, USA, 2008. View at Google Scholar